Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of next-generation synthetic binders for the life sciences industry, has announced that the Company will be presenting at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Brewery Place, Leeds, LS10 1NE. Event registration opens at 4.30 pm and presentations commence at 5.00 pm.

Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial Officer, will deliver a presentation, offering investors the opportunity to engage directly with the Company and gain valuable insights into its recent progress.

For further information on the ShareSoc Growth Company Seminar and registration, please visit the event website: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/

A link to Aptamer’s presentation will be made available on the Company website following the event.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group delivers 40% revenue growth and expands licensing portfolio

    Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.

    Aptamer Group secures repeat contract for Optimer® binder development

    Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

    Aptamer Group to announce full year 2025 results on 14 October

    Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. .

    Aptamer Group secures £360,000 contract with top 3 global pharma

    Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Aptamer signs contract with Metir for Cryptosporidium detection binders

    Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

      Search

      Search